688580.SHG Nanjing Vishee Medical Technology Co Ltd
- Market cap
- CNY 3.76B
- P/E
- 23.5x
- P/B
- 2.05x
- ROE
- 9.6%
- Dividend yield
- 2.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688580.SHG undervalued?
Graham number688580.SHG trades 46.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanjing Vishee Medical Technology Co Ltd fundamental analysis
No fundamental analysis for Nanjing Vishee Medical Technology Co Ltd yet.
Nanjing Vishee Medical Technology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanjing Vishee Medical Technology Co Ltd
Nanjing Vishee Medical Technology Co., Ltd provides rehabilitation meditation products and solutions in China and internationally. The company offers MagNeuro, a transcranial magnetic stimulation (TMS) device, and MagNeuro ONE, a TMS therapy system with navigation for psychiatric and neurological applications. It also provides MagBelle, a pelvic floor muscle stimulator for the treatment of urinary incontinence, rehabilitation of weak pelvic muscles, and restoration of neurom…
Full company profileNanjing Vishee Medical Technology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nanjing Vishee Medical Technology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 95.9M | 144M | 208M | 319M | 378M | 430M | 322M | 462M | 400M | 463M | 433M |
| Gross Profit | 70.4M | 106M | 154M | 235M | 279M | 322M | 233M | 313M | 262M | 463M | 285M |
| Operating Income | 20.3M | 46.8M | 72.0M | 115M | 165M | 195M | 104M | 148M | 112M | 151M | 128M |
| EBITDA | 19.0M | 47.5M | 77.6M | 124M | 175M | 207M | 122M | 170M | 135M | 173M | 187M |
| Net Income | 23.1M | 40.3M | 63.4M | 99.7M | 144M | 178M | 93.8M | 136M | 102M | 137M | 165M |
| EPS | 0.46 | 0.57 | 0.88 | 1.39 | 1.76 | 1.85 | 0.98 | 1.42 | 1.07 | 1.43 | 1.73 |
| Balance Sheet | |||||||||||
| Total Assets | 170M | 247M | 308M | 404M | 1.54B | 1.64B | 1.68B | 1.81B | 1.82B | 1.91B | 1.81B |
| Total Liabilities | 51.5M | 93.1M | 112M | 149M | 129M | 106M | 156M | 179M | 193M | 216M | 91.8M |
| Shareholders' Equity | 118M | 144M | 187M | 249M | 1.41B | 1.53B | 1.53B | 1.63B | 1.63B | 1.69B | 1.71B |
| Cash & Short-term Investments | 93.5M | 135M | 162M | 244M | 1.37B | 1.37B | 1.25B | 1.15B | 1.07B | 1.02B | 873M |
| Total Debt | - | 20.0M | 19.5M | 14.0M | 4.17M | 2.99M | 1.19M | 27.1M | 897K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 31.0M | 52.3M | 85.8M | 141M | 121M | 157M | 86.2M | 134M | 118M | 177M | - |
| Capital Expenditure | 17.4M | 14.5M | 40.9M | 21.2M | 11.7M | 87.3M | 95.6M | 133M | 113M | 118M | 135M |
| Free Cash Flow | 13.6M | 37.8M | 44.9M | 120M | 109M | 70.0M | -9.45M | 716K | 5.21M | 58.6M | -27.9M |
| Ratios | |||||||||||
| ROE | 19.6% | 28.0% | 33.8% | 40.0% | 10.2% | 11.6% | 6.1% | 8.4% | 6.3% | 8.1% | 9.6% |
| ROA | 13.6% | 16.4% | 20.5% | 24.7% | 9.3% | 10.9% | 5.6% | 7.5% | 5.6% | 7.2% | 9.2% |
| Net Profit Margin | 24.1% | 27.9% | 30.5% | 31.3% | 38.0% | 41.3% | 29.2% | 29.5% | 25.5% | 29.5% | 38.2% |
| Debt to Equity | - | 0.14x | 0.10x | 0.06x | 0.00x | 0.00x | 0.00x | 0.02x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nanjing Vishee Medical Technology Co Ltd dividends
- Dividend yield
- 2.04%
- Forward dividend
- 1.08 CNY
- Payout ratio
- 56.0%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 76.6M | 0.80 | 56.0% |
| 2024 | CNY 102M | 1.07 | 100.2% |
| 2023 | CNY 51.0M | 0.53 | 37.5% |
| 2022 | CNY 88.9M | 0.93 | 94.8% |
| 2021 | CNY 71.8M | 0.75 | 40.4% |
| 2020 | CNY 50.3M | 0.62 | 35.0% |
| 2019 | CNY 37.8M | 0.53 | 37.9% |
| 2018 | CNY 21.0M | 0.29 | 33.1% |
| 2017 | CNY 24.5M | 0.35 | 60.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 5, 2024.
Who owns Nanjing Vishee Medical Technology Co Ltd
- Insiders 65.35%
- Institutions 2.25%
- Public & others 32.40%
- Shares outstanding 95.8M
- Free float 36.0M
Nanjing Vishee Medical Technology Co Ltd company profile
- Company name
- Nanjing Vishee Medical Technology Co Ltd
- Ticker
- 688580.SHG
- ISIN
- CNE1000041Q0
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 635
- Fiscal year end
- December
- Address
- Building 9, Nanjing, China, 210012
- Phone
- 86 25 6967 0888
- Website
- vishee.com
About Nanjing Vishee Medical Technology Co Ltd
Nanjing Vishee Medical Technology Co., Ltd provides rehabilitation meditation products and solutions in China and internationally. The company offers MagNeuro, a transcranial magnetic stimulation (TMS) device, and MagNeuro ONE, a TMS therapy system with navigation for psychiatric and neurological applications. It also provides MagBelle, a pelvic floor muscle stimulator for the treatment of urinary incontinence, rehabilitation of weak pelvic muscles, and restoration of neuromuscular control; MagGraver, a powered muscle stimulator for use in abdominal sculpting and body sculpting applications; and RFIntima, a radiofrequency medical device. The company was founded in 2001 and is headquartered in Nanjing, China.
Nanjing Vishee Medical Technology Co Ltd management
9- Mr. Zhiyu WangGM & Chairman of the Board · born 1967
- Ms. Chen LiliDeputy GM, CFO & Director · born 1980
- Mr. Zhang HuiDeputy GM & Director · born 1981
- Ms. Yihong TongSenior Director of Strategic Investment Department & Secretary of the Board · born 1985
- Mr. Kai QiuDeputy General Manager · born 1985
- Mr. Fei GaoSenior Director of R&D Department · born 1986
- Mr. Chuan HanDeputy General Manager · born 1980
- Wenjing YaoAccounting Supervisor
- Mr. Wenlong LiuMarketing Director · born 1988